University of Thessaly, Larissa, Greece

Slides:



Advertisements
Similar presentations
Copyright © 2002 Pearson Education, Inc. Slide 1.
Advertisements

Governance of a Stroke Thrombolysis Service
2 Canadian Neurological Scale: Training for Trainers Workshop An Introduction.
TPA in Stroke: What's All the Fuss?. FERNE Brain Illness and Injury Course.
Improving Psychological Care After Stroke
The NINDS rt-PA Stroke Trial Prior information(Pre-Clinical, Phase I Studies, etc) Thrombolytic canalization of occluded arteries may reduce the degree.
G.N. Dalekos3, M. Elisaf2, A.I. Hatzitolios1
Richard Shih, MD, FACEP Stroke Patient and ED Stroke Therapy Assessments: What Does Every Emergency Physician Need to Know About the NIHSS & Other Stroke.
Prediction Models in Medicine Clinical Decision Support The Road Ahead Chapter 10.
Centre Cérébrovasculaire PREDICTIVE VALUE OF THE ASTRAL SCORE, THE CHARLSON AND THE ELIXHAUSER COMORBIDITY INDEXES IN ACUTE ISCHEMIC STROKE Kakaletsis.
Centre Cérébrovasculaire COMORBIDITY ANALYSIS AND 3 MONTHS FUNCTIONAL OUTCOME IN ACUTE ISCHEMIC STROKE: DATA FROM ACUTE STROKE REGISTRY AND ANALYSIS.
Types of Control I. Measurement Control III. Experimental Control II. Statistical Control (Reliability and Validity) (Internal Validity) (External Validity)
Evidence Based Medicine for the Athletic Trainer: What is It?
Andrew Asimos, MD, FACEP Stroke Patient and Stroke Therapies Assessment: ED NIHSS & Stroke Scales Use for ED Stroke Therapies.
T-PA in Treatment of Acute Stroke: What We Know From NINDS 2004 vs 2000 Sidney Starkman, MD Departments of Emergency Medicine and Neurology, UCLA UCLA.
Acute Stroke Management in Northern Nevada and the Sierra Slopes A Model for Rural Stroke Care Paul M. Katz, M.D. Medical Director Washoe Comprehensive.
Efficiency of stroke clinical trials with ordinal outcomes: a simulation study UPC, Julio 2010 BASEL, October 2011 Juan Vicente Torres Supervisors: Dr.
Validation of Mayo Clinic Risk Adjustment Model for In-Hospital Mortality following Percutaneous Coronary Interventions using the National Cardiovascular.
Using stroke scales to assess the patient – Rankin and NIHSS
1 Statin treatment is associated with improved prognosis in patients with AF-related stroke G. Ntaios, V. Papavasileiou, K.Makaritsis, A.Karagiannaki,
The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Brief Protocol Training NIH-NINDS U01 NS NETT CCC U01 NS NETT SDMC U01 NS
Lecture 6: Reliability and validity of scales (cont) 1. In relation to scales, define the following terms: - Content validity - Criterion validity (concurrent.
Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Risk Assessment Farrokh Alemi, Ph.D.. Session Objectives 1.Discuss the role of risk assessment in the TQM process. 2.Describe the five severity indices.
Revision of key terms Write down the 12 key terms for the definitions on the slides.
Part of a presentation given at the Canadian Nutrition Society Conference Manon Laporte PDt, MSc June 2013.
Advanced Research Methods Unit 3 Reliability and Validity.
TEMPERATURE CHANGE, SHORT- AND LONG-TERM MORTALITY IN ACUTE ISCHEMIC STROKE Kakaletsis Nikolaos 1, Papavasileiou Vasileios 1, Lambrou Dimitrios 2, Ntaios.
Measurement in CVA Addendum slides. Wonderful resource McGill University in Canada has a website called the Stroke Engine. It has best evidence for a.
TIGER Standards & Interoperability Collaborative Style Guide for Tutorials.
Introduction to Item Analysis Objectives: To begin to understand how to identify items that should be improved or eliminated.
2014 IHP+ monitoring: December Round of Monitoring Development Effectiveness in Health Summary of Findings (being validated) 12 December 2014.
NODE 0 mRS 0: 13.6% (n=551) mRS 1: 19.4% (n=785) mRS 2: 14.7% (n=597) mRS 3: 16.5% (n=668) mRS 4: 21.1% (n=855) mRS 5: 7.0% (n=324) mRS 6: 6.7% (n=271)
TEMPERATURE CHANGE, SHORT- AND LONG-TERM HANDICAP IN ACUTE ISCHEMIC STROKE Kakaletsis Nikolaos 1, Papavasileiou Vasileios 1, Lambrou Dimitrios 2, Ntaios.
Long-Term Outcomes after Acute Stroke Treatment Larry B. Goldstein, M.D. Professor of Medicine (Neurology) Center for Cerebrovascular Disease Center for.
Sapienza University of Rome (Italy), University of Oxford (UK),Uppsala University (Sweden), University Hospitals, Cambridge (UK), Hospital Amato Lusitano,
Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Elevated Plasma Levels of Neuropeptide Proenkephalin.
Return to Home! Go To Next Slide! Return to Home! Go To Next Slide!
Statistics Unit Check your understanding…. Can you answer these? What does the standard deviation of a sample represent? What is the difference between.
Olivier Bill 1,2, Guillermo Toledo Sotomayor 1, Ivo Meyer 2, Patrik Michel 2, Tiago Moreira 3 Julien Niederhauser 1, Lorenz Hirt 2. 1 Stroke Unit, GHOL,
3 Year Stroke Survivors: The Impact of Stroke on Cognition and Factors Associated with Long Term Recovery Susan Mahon PhD Student Recipient Neurological.
Impact of School Culture: Part-Time MBA Programs
Keystone Heart Reflect Neurology
Hemicraniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke DESTINY II TRIAL Katherine Steele 7 April 2014.
Multimodal Predictors of Massive Ischemic Stroke & Favourable Outcome.
Copyright © 2010 American Medical Association. All rights reserved.
Imaging biomarkers of post-stroke prognosis
Olivier Bill1,3, Nuno M Inácio2, Dimitrios Lambrou1, Patrik Michel1.
Economic evaluation: readiness in practice settings
Low Pulse Pressure After Acute Ischemic Stroke is Associated With Unfavorable Outcomes: The Taiwan Stroke Registry by Sung‐Chun Tang, Jiu‐Haw Yin, Chung‐Hsiang.
The Process of Rehabilitation and Discharge Planning in Stroke
Improving retention: Using a voluntary diagnostic quiz
Clinical Policy: Use of Intravenous tPA for the Management of Acute Ischemic Stroke in the Emergency Department    Annals of Emergency Medicine  Volume.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
Volume 14, Issue 5, Pages (May 2015)
Types of Control I. Measurement Control II. Statistical Control
Early Scandinavian Stroke Scale Scores as a Predictive Tool for Rehabilitation and Discharge Planning Brett Jones1, Ronak Patel2,3, Christian Lueck1,3.
Three Steps to Interpret Clinical Trials
Thrombolysis for acute ischemic stroke
Volume 14, Issue 5, Pages (May 2015)
This is… 2 DOUBLES 4→10 EARLY NUMBER SENSE.
No Financial Disclosure or Conflict of Interest
Modified Rankin Scale (mRS) scores were evaluated as a measure of neurological outcome function of participants from 30 to 180 days after stoke. Modified.
Three outcome measures from the NINDS tPA trial
National Institutes of Health Stroke Scale (NIHSS) scores were evaluated as a measure of neurological deficit in patients within 30 days, and the Barthel.
Modified Rankin Scale (mRS) scores were evaluated as a measure of neurological outcome function of participants from 30 to 180 days after stoke. Modified.
Cases. Simple Regression Linear Multiple Regression.
This is… 7 DOUBLES 12→20 EARLY NUMBER SENSE.
National Institutes of Health Stroke Scale (NIHSS) scores were evaluated as a measure of neurological deficit in patients within 30 days, and the Barthel.
Rasch Analysis of the Barthel Index in the Assessment of Hospitalized Older Patients After Admission for an Acute Medical Condition  Natalie A. de Morton,
Presentation transcript:

University of Thessaly, Larissa, Greece The ASTRAL score to predict functional outcome in acute ischemic stroke George Ntaios University of Thessaly, Larissa, Greece

Dear colleagues, I would like first to thank the organizing committee for the kind invitation to be here today and discuss with you about the ASTRAL score. I am sure that it happened to all of us that a patient who was just admitted with stroke or his relatives ask us if he will be able walk again, if he will be able to go back to work again, and generally if he is going to be independent again. I don’ t know how you respond to these questions, but until recently I used to answer that it is not possible at admission to make a safe prediction about the future of the patient, and that we need at least a few more days. So, actually, this is the question that we tried to answer with this study, that is to see if it possible to predict patient’s outcome right away from the very first minutes after stroke onset.

Let’s design the ideal prognostic score… not too many variables readily available variables simple to calculate applicable as early as possible widely-used scale for outcome assessment validated externally validated in large population validated in multiple populations So, when we started designing this study, we spent a few days thinking how should the ideal stroke prognostic score look like. And, we came down to the following characteristics: first of all, the ideal score should not include too many variables. When a score includes many variables, it is not very user-friendly and as a result, doctors are relatively reluctant to use it. Secondly, the ideal score should include variables which are easy to assess. For example, imagine a stroke prognostic score which includes the penumbra volume. How many centers around the world do you think that would be able to use such a score in everyday clinical practice? Then, the ideal prognostic score should be calculated easily without complex mathematical formulas or the use of calculators. Also, the ideal prognostic score should be applied as early as possible after stroke onset. I mean, we can all make a decent guess about the patient’s future at discharge, so we would not really need a prognostic score at discharge. Also, it is important that to use a widely-used scale is used for the assessment of outcome. There are several indices of outcome like the modified Rankin scale score, the Barthel index, the Glasgow outcome scale, the Oxford Handicap scale and many other. Among them, probably the modified Rankin Scale score is the most widely used. Also, the ideal prognostic score should be externally –not internally- validated (we will discuss a bit more about this in a few minutes). Finally, the ideal prognostic score should be validated in a large population and if possible, in multiple populations. Modified Rankin Scale score Barthel index Glasgow outcome scale Oxford Handicap Scale

ASTRAL registry (Lausanne/Switzerland) n=1645 Athens Stroke Registry n=1659 Vienna Stroke registry n=653 Development of the prognostic score Double external validation of the prognostic score Prognostic point-based score Color chart So, keeping these things in mind, this is how we designed our study in order to develop a prognostic score for the prediction of stroke outcome. We used data from the ASTRAL registry, which is the registry of all consecutive patients admitted in CHUV hospital in Lausanne, Switzerland since 2003. Several parameters are registered in this registry such as demographics, patient history, clinical examination, imaging findings, laboratory data and treatment modalities. We included all these parameters in a multivariate analysis using poor outcome as the endpoint, defined as modified Rankin Scale score of 3 or more. The parameters which were shown to be independent predictors of outcome in this multivariate analysis were used to construct the prognostic score. Then, the next step would be to validate the performance of our score. A validation can be either internal of external. In internal validation, what you actually do is split your dataset in two randomly chosen groups, you use the first group to develop your score, and then you use the second group to validate the performance of the score. However, taken into consideration that actually both groups come from the same mother population, an internal validation is not so reliable. On the contrary, the external validation means that you use your full dataset to develop your score and then you use an external independent population to validate the performance of the score. So, we decided to validate our score externally, and for this reason we used the data from the Athens Stroke registry. But we wanted to be strict with our score, so we decided to look for a second external validation in another population and so, we used also the data from the Vienna Stroke registry. Finally, we wanted to make this score as user-friendly as possible, so we aimed to draw a color chart which would help predict stroke outcome in daily clinical practice easily without any need for mathematical formulas or calculators.

If we have a look at the baseline characteristics of the 16 hundred patients from the ASTRAL registry who were used to develop the score, we can see that their median age was 68 years, their mean NIHSS was 9, 32% of them had a visual defect, 90% of them were fully alert, and their mean BP was 160 over 96.

So, as we already mentioned, we performed a multivariate analysis of all available parameters using poor outcome as the dependent variable, defined as Rankin score of 3 or more. The results showed six independent predictors of outcome which were age, stroke severity assessed with the NIHSS score, the time between stroke onset and hospital admission, the range of vision, glucose value at admission and level of consciousness. And as you can see, the acronym ASTRAL comes from the first letters of these parameters. Now, from these analysis, we used the beta-coefficients, which actually show the relative contribution of each parameter in the prediction of outcome, and we multiplied them with the number four. Then we rounded them to the closest digit.

So, this is how the ASTRAL score was developed So, this is how the ASTRAL score was developed. And as we can see, a patient gets 1 point for every 5 years of age, 1 point for every 1 point in the NIHSS score, 2 points if admitted later than 3 hours after stroke onset, two points if there is a visual field defect, 1 point if his admission glucose is higher than 7.3 or less than 3.7 mmol/lt and 3 points if his level of concsiousness is impaired. The sum of all these points gives the overall score.

Now, the blue bars in this diagram show the number of patients in the Lausanne registry for every given value of the ASTRAL score. So, for example, the ASTRAL score was 17 in approximately 100 patients, and 25 in almost 50 patients. As we can see, most patients had an ASTRAL score between 15 and 25. Now, the S-curve, the sigmoid curve shows the probability of poor outcome for every given value of the ASTRAL score. In general, the higher the ASTRAL score, the worse the outcome is. So for example, a patient with an ASTRAL score of 22 has only 20% probability of bad outcome, a patient with a score of 30 has a 50% possibility of bad outcome, and a patient with 38 has more than 80% probability of bad outcome.

P=0.43 Now, for any prognostic score, in order to see if this score is reliable, we can use two statistical tools. The first one is called calibration, that is the agreement between predicted and actual outcome. And this graph shows that the internal calibration for our score was very good. The S-curve shows again the predicted possibility of bad outcome for any given value of the ASTRAL score, as this is calculated by the mathematical model. The yellow dots show the actual outcome of the registered patients. As we see, the dots fall very very close to the S-curve, which means that the actual outcome of the patients was very similar to the predicted outcome. Ίσως κάποιος σχολιάσει ότι στα δύο άκρα της καμπύλης τα όρια εμπιστοσύνης είναι πιο μεγάλα, αλλά αυτό δεν οφείλεται σε μειωμένη αξιοπιστία του σκορ σε εκείνες τις περιοχές, αλλά σε μικρότερο πλήθος ασθενών με αντίστοιχα σκορ. Calibration, i.e., the agreement between predicted and actual outcome, was assessed in the derivation and validation cohorts with the use of the Hosmer-Lemeshow goodness-of-fit test with 10 groups

The second statistical tool to see if a prognostic score is reliable is called discrimination, that is the efficiency of the score to discriminate between patients with good and bad outcome. This is assessed by calculating the area under the curve or else, AUC. So, in the internal discrimination of our score, the AUC was 0.85 which is a really excellent result.

ASTRAL registry (Lausanne/Switzerland) n=1645 Athens Stroke registry n=1659 Vienna Stroke registry n=653 Development of the prognostic score Double external validation of the prognostic score Prognostic point-based score Color chart So, as soon as the score was developed, the next step was to validate it. As we already mentioned, we chose to validate it externally, in two independent stroke registries: the Athens stroke registry and the Vienna stroke registry.

As we can see, the basic characteristics of the three cohorts were similar, with the main difference being that the Austrian strokes were less severe.

P=0.22 The external validation of the score is again assessed using the tools of calibration and discrimination. We see that the calibration in the Athens cohort is really excellent as the dots –which show the actual outcome- fall very close to the S-curve –which shows the predicted probability of outcome.

P=0.49 The calibration of the score in the Vienna registry is not so excellent like in the Athens cohort , but still is very good and of course statistically significant.

P=0.82 Now, if we combine the Athens and Vienna registries, we can see again that the score has an excellent calibration in this pooled dataset.

The second statistic tool to assess external validity of the score is the discrimination. And as we see, the discrimination of the score in the Athens cohort is really excellent, since the area under the curve is really impressive: 0.93.

The area under the curve in the Vienna registry is not so impressive like in the Athens registry, but still it is very good: 0.77

Now if we pool the Athens and the Vienna registries together, the area under the curve has again an excellent, a very convincing value of 0.90.

ASTRAL registry (Lausanne/Switzerland) n=1645 Athens Stroke Registry n=1659 Vienna Stroke Registry n=653 Development of the prognostic score Double external validation of the prognostic score Prognostic point-based score Color chart So, we just saw that the ASTRAL score was externally validated in a very convincing way. So, the final step in our project was to draw a color chart to make our score even more user friendly.

So, this is the graph that we have drawn So, this is the graph that we have drawn. In this graph, the possibility of poor outcome is pre-calculated according to the values that each parameter may have and is represented in a color palette. So, let’s see how to use this graph. The first parameter that we examine is if there is visual field defect. And let’ s consider a patient with no visual field defect, so we focus on the upper part of the graph. Then, we examine his admission glucose, so if it between 3.7 and 7.3, for example 5.1, then we focus on the left part of the graph. Then, we examine his level of consciousness, and if it is good we focus on the left part. Then we examine how soon after stroke onset was he admitted, and if he arrived within less than three hours we focus on the lower part of the graph. Then, we examine the patient’s age and if for example it is 68 years we focus on a specific line. And finally, we examine stroke severity, so if it is 5 for example, we focus to this little square. The color of this little square corresponds to the possibility of bad outcome, as described in the color palette at the lower part of the graph. So, for example, the patient that we just described has a 10-20% possibility of bad outcome.

the ASTRAL score is a very reliable prognostic score Take-home messages the ASTRAL score is a very reliable prognostic score it calculates the probability of poor outcome at three months it can be used already at admission it is very simple to use, especially with the help of the color chart So, to conclude, the ASTRAL score is……. Before I close, I would like to thank these people for being so nice to work with: Dr Patrik Michel and Mohamed Faouzi from Lausanne, Dr Kostas Vemmos from Athens, and Dr Julia Ferrari and Prof Wilfried Lang from Vienna. Thank you.

Spare slides

Oxford Handicap Scale score < 3 Now, let’s see some other prognostic scores that can be used to predict stroke outcome. And allow me to start with a prognostic score which was introduced and published in 2002 in Stroke. From my point of view, this score has two major weaknesses which limit the wide applicability of the score in clinical practice. Firstly, the outcome scale is the Oxford Handicap Scale score, which as far as I know, is not used very often. Actually, how many of us use this scale to assess our patient’s outcome?......(pause)….. Oh, I see, not so many…. The second major weakness is that it is too complex to calculate. As is described in the paper, you need to use this following formula taken into consideration these numbers. Well, you certainly need a calculator for this! Stroke 2002; 33: 1041-1047

logit(BI<95) = -5.782 + (0.049*age) + (0.272*NIHSS) This is another score introduced in 2004 in Stroke again. The advantage of this score is that it includes only two parameters, the age and the NIHSS. On the other hand, a little weakness is that it uses the Barthel index to assess stroke outcome, which is not so widely used as the Rankin score. At the beginning, there was also another major weakness, which again was the complexity of the score. As you see, you had to calculate the possibility of bad outcome using this complex formula. Stroke 2004;35:158-162

Fortunately, after a while, the authors introduced a normogram which helps to assess the possibility of good outcome without any complex calculations. So, how it works? First you find the age of the patient, which corresponds to some points at the first axis. Then, you assess stroke severity which corresponds to some more points at the first axis. Then, you add these points, and you get a sum which corresponds to the possibility of good outcome. Stroke 2008;39;1821-1826

- Validation in the VISTA dataset ASTRAL score Score by Weimar et al. - Validation in the VISTA dataset ASTRAL score - Validation in pooled Athens/Vienna dataset This score was externally validated in the VISTA dataset. The area under the curve was 0.80, which is a very good result showing that this prognostic score is reliable. However, please allow me to notice that this result is still far from the result of the validation of our score, which was 0.90 in a double external validation. Stroke 2008;39;1821-1826 Neurology 2012;78:1916–1922

Recently, another prognostic score was introduced, the iSCORE. Stroke 2011;42:3421-3428

It was recently shown that the iSCORE can predict stroke outcome It was recently shown that the iSCORE can predict stroke outcome. As can be seen in the figure, the higher the iSCORE, the higher the probability of mortality or disability at 30 days. Stroke 2011;42:3421-3428

The iSCORE can be calculated easily taken into consideration several parameters such as age, sex, stroke severity, stroke subtype, atrial fibrillation, heart failure, cancer, renal dialysis, preadmission disability and admission glucose. However, we need to point out that perhaps the major weakness of the iSCORE is that stroke severity needs to be assessed using the Canadian Neurological Scale which is again not so widely used. I wonder, how many of us do we regularly use the Canadian Neurological Scale to assess stroke severity in your patients….(pause)….. I see, not many… Stroke 2011;42:3421-3428

Συνοψίζοντας λοιπόν, προτείνουμε ένα νέο εύχρηστο και αξιόπιστο τρόπο για την πρόγνωση της έκβασης στα ισχαιμικά αγγειακά εγκεφαλικά επεισόδια. Ευχαριστώ!

P=0.43 P=0.22 P=0.49 P=0.82 Το πάνω αριστερό διάγραμα το είδαμε και προηγουμένως και δείχνει την σύμπτωση μεταξύ της προβλεπόμενης και της πραγματικης έκβασης του επεισοδίου στην ομάδα της Λωζάννης. Πάνω δεξιά βλέπουμε το ίδιο διάγραμμα ια την ομάδα της Αθήνας όπου και πάλι βλέπουμε πόσο πολύ συμπίπτουν. Κάτω δεξιά βλέπουμε την ομάδα της Αυστρίας όπου η σύμπτωση λιγότερο εντυπωσιακή, ενώ στο τέταρτο διάγραμμα όπου έχουν συνδυαστεί οι ασθενείς της Αθήνας και της Αυστρίας εη σύμπτωση είναι επίσης εξαιρετική. Hosmer-Lemeshow test

The Τα παραπάνω αντικατοπτρίζονται και στις areas under the curve, οι οποίες ήταν 0.85 όπως είδαμε στην ομάδα της Λωζάννης, ένα εξαιρετικά εντυπωσιακό 0.93 στην ομάδα της Αθήνας, 0.77 στην ομάδα της Αυστρίας, και επίσης ένα εντυπωσιακό 0.90 στο συνδυασμό της Αθήνας και της Αυστρίας.

Τα παραπάνω αντικατοπτρίζονται και στις areas under the curve, οι οποίες ήταν 0.85 όπως είδαμε στην ομάδα της Λωζάννης, ένα εξαιρετικά εντυπωσιακό 0.93 στην ομάδα της Αθήνας, 0.77 στην ομάδα της Αυστρίας, και επίσης ένα εντυπωσιακό 0.90 στο συνδυασμό της Αθήνας και της Αυστρίας.

Predictors of long-term outcome 5-year unfavourable outcome (mRS=3-6) 5-year mortality ASTRAL score (per 1 point increase) 1.09 (1.08 – 1.10)* Atrial fibrillation 1.53 (1.14 – 2.04)† Heart Failure 1.56 (1.14 – 2.13)† Stroke subtypes 1 Lacunar 1.71 (1.10 – 2.66)‡ 1.14 (0.67 – 1.94) Atherosclerotic 1.65 (1.03 – 2.63)‡ 1.74 (1.02 – 2.97)‡ Cardioembolic 2.82 (1.84 – 4.34)* 2.39 (1.46 – 3.93)* Undetermined 0.74 (0.58 – 0.95)‡